Nasdaq-listed MoonLake Immunotherapeutics, a Switzerland-based clinical-stage biotech company focused on creating next-level therapies for inflammatory diseases, has entered into an agreement with Hercules Capital, a provider of customized debt financing…
Switzerland: MoonLake secures up to US$500m in non-dilutive financing
…
…






